Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Treatment of cachexia: melanocortin and ghrelin interventions.

Steinman J, DeBoer MD.

Vitam Horm. 2013;92:197-242. doi: 10.1016/B978-0-12-410473-0.00008-8. Review.

PMID:
23601426
2.

Control of food intake and muscle wasting in cachexia.

Amitani M, Asakawa A, Amitani H, Inui A.

Int J Biochem Cell Biol. 2013 Oct;45(10):2179-85. doi: 10.1016/j.biocel.2013.07.016. Epub 2013 Jul 30.

PMID:
23911307
3.

Melanocortin interventions in cachexia: how soon from bench to bedside?

DeBoer MD.

Curr Opin Clin Nutr Metab Care. 2007 Jul;10(4):457-62. Review.

PMID:
17563464
4.

Ghrelin and cachexia: will treatment with GHSR-1a agonists make a difference for patients suffering from chronic wasting syndromes?

DeBoer MD.

Mol Cell Endocrinol. 2011 Jun 20;340(1):97-105. doi: 10.1016/j.mce.2011.02.012. Epub 2011 Feb 25. Review.

5.

Update on melanocortin interventions for cachexia: progress toward clinical application.

DeBoer MD.

Nutrition. 2010 Feb;26(2):146-51. doi: 10.1016/j.nut.2009.07.003. Epub 2009 Dec 8. Review.

6.

The role of ghrelin in anorexia-cachexia syndromes.

Guillory B, Splenser A, Garcia J.

Vitam Horm. 2013;92:61-106. doi: 10.1016/B978-0-12-410473-0.00003-9. Review.

PMID:
23601421
7.

Therapeutic applications of ghrelin to cachexia utilizing its appetite-stimulating effect.

Akamizu T, Kangawa K.

Peptides. 2011 Nov;32(11):2295-300. doi: 10.1016/j.peptides.2011.05.018. Epub 2011 May 23. Review.

PMID:
21635929
8.

Ghrelin and cachexia in chronic kidney disease.

Suzuki H, Asakawa A, Amitani H, Nakamura N, Inui A.

Pediatr Nephrol. 2013 Apr;28(4):521-6. doi: 10.1007/s00467-012-2241-6. Epub 2012 Jul 4. Review.

PMID:
22760416
9.

Ghrelin and its therapeutic potential for cachectic patients.

Ashitani J, Matsumoto N, Nakazato M.

Peptides. 2009 Oct;30(10):1951-6. doi: 10.1016/j.peptides.2009.07.002. Epub 2009 Jul 10. Review.

PMID:
19595727
10.

Neuropeptides in the pathophysiology and treatment of cachexia.

Krasnow SM, Marks DL.

Curr Opin Support Palliat Care. 2010 Dec;4(4):266-71. doi: 10.1097/SPC.0b013e32833e48e7. Review.

11.

Therapy insight: Use of melanocortin antagonists in the treatment of cachexia in chronic disease.

DeBoer MD, Marks DL.

Nat Clin Pract Endocrinol Metab. 2006 Aug;2(8):459-66. Review.

PMID:
16932335
12.

Emergence of ghrelin as a treatment for cachexia syndromes.

DeBoer MD.

Nutrition. 2008 Sep;24(9):806-14. doi: 10.1016/j.nut.2008.06.013. Review.

PMID:
18725076
13.

Cachexia: lessons from melanocortin antagonism.

Deboer MD, Marks DL.

Trends Endocrinol Metab. 2006 Jul;17(5):199-204. Epub 2006 Jun 5. Review.

PMID:
16750633
14.

Genetic and pharmacologic blockade of central melanocortin signaling attenuates cardiac cachexia in rodent models of heart failure.

Scarlett JM, Bowe DD, Zhu X, Batra AK, Grant WF, Marks DL.

J Endocrinol. 2010 Jul;206(1):121-30. doi: 10.1677/JOE-09-0397. Epub 2010 Apr 6.

15.

Cancer cachexia pathophysiology and translational aspect of herbal medicine.

Suzuki H, Asakawa A, Amitani H, Fujitsuka N, Nakamura N, Inui A.

Jpn J Clin Oncol. 2013 Jul;43(7):695-705. doi: 10.1093/jjco/hyt075. Epub 2013 Jun 4. Review.

16.
17.

Ghrelin for cachexia.

Akamizu T, Kangawa K.

J Cachexia Sarcopenia Muscle. 2010 Dec;1(2):169-176. Epub 2010 Dec 17.

18.

Central mechanisms controlling appetite and food intake in a cancer setting: an update.

Fletcher AL, Marks DL.

Curr Opin Support Palliat Care. 2007 Dec;1(4):306-11. doi: 10.1097/SPC.0b013e3282f14c4e. Review.

PMID:
18685380
19.

Emerging results of anticatabolic therapy with ghrelin.

Akamizu T, Kangawa K.

Curr Opin Clin Nutr Metab Care. 2007 May;10(3):278-83. Review.

PMID:
17414495
20.

The role of ghrelin and ghrelin analogues in wasting disease.

Kamiji MM, Inui A.

Curr Opin Clin Nutr Metab Care. 2008 Jul;11(4):443-51. doi: 10.1097/MCO.0b013e328303dee4. Review.

PMID:
18542005
Items per page

Supplemental Content

Write to the Help Desk